REC Interventional Cardiology最新文献

{"title":"Transcatheter mitral edge-to-edge repair vs optimal medical therapy in secondary mitral regurgitation: a meta-analysis.","authors":"Daniel Paulino-González, Miguel A Pardiño-Vega, Arantza Lizbeth García-Loera, Karoly P Zúñiga-Montaño, Daniel A Navarro-Martínez","doi":"10.24875/RECICE.M25000558","DOIUrl":"10.24875/RECICE.M25000558","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Mitral regurgitation is one of the most common heart valve diseases. Valve replacement surgery is a guideline-recommended option; however, in a significant proportion of patients, this option is not feasible. In such cases, mitral transcatheter edge-to-edge repair (M-TEER) is a potential therapeutic alternative. Nevertheless, the results of a randomized clinical trial have shown divergent results. Recently, the results of the RESHAPE-HF2 trial were published, providing additional insights. The objective of this work is to evaluate whether there are any differences between performing M-TEER and keeping patients under guideline-directed medical therapy (GDMT).</p><p><strong>Methods: </strong>We conducted a meta-analysis following the PRISMA guidelines. We searched for studies across the PubMed, Embase, and Cochrane databases until February 2025. We establish the following inclusion criteria: patients with secondary mitral regurgitation, studies comparing M-TEER plus GDMT vs GDMT alone, and who reported hospitalization due to heart failure (HF) or mortality.</p><p><strong>Results: </strong>A total of 3 randomized clinical trials meet the inclusion criteria, including a total of 1423 patients: 704 received M-TEER and 719, GDMT alone. M-TEER was associated with a reduced risk of HF-related hospitalization with a risk ratio (RR) of 0.71 (95%CI, 0.56-0.90; P = .004). We did not find any differences in all-cause mortality with a RR of 0.80 (95%CI, 0.63-1.02; P = .07).</p><p><strong>Conclusions: </strong>In this meta-analysis, M-TEER plus GDMT shows a lower risk of HF-related hospitalization vs GDMT alone. We did not find any differences in the risk of all-cause mortality or cardiac death.Registered at PROSPERO: CRD42025645047.</p>","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"8 3","pages":"143-151"},"PeriodicalIF":1.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13532097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"VerifyNow in acute coronary syndrome: design of the EPIC17-VERONICA trial to optimize platelet inhibition.","authors":"Celia Garilleti Cámara, José María de la Torre-Hernández, José Ramón Rumoroso Cuevas, Sebastián Romaní, Andrea Virginia Monastyrski, Alejandro Diego Nieto, Jeremías Bayón Lorenzo, Héctor Cubero Gallego, Joan Antoni Gómez-Hospital, Nuria Vallejo Calcerrada, Ainhoa Pérez Guerrero, Ignacio J Amat-Santos, Vicente Alcalde Martínez, Ramón López-Palop, Javier Jimeno Sánchez, Armando Pérez de Prado, Íñigo Lozano Martínez-Luengas","doi":"10.24875/RECICE.M25000544","DOIUrl":"10.24875/RECICE.M25000544","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>De-escalation from prasugrel and ticagrelor to clopidogrel in patients undergoing percutaneous coronary intervention after acute coronary syndrome (ACS) is a strategy aimed at reducing bleeding. This study evaluates whether VerifyNow (Werfen, Spain)-guided de-escalation, based on platelet aggregation measurement, provides a therapeutic benefit in ACS management.</p><p><strong>Methods: </strong>This ongoing multicenter, prospective, randomized 1:1 trial will enroll 634 patients with ACS who underwent revascularization with a sirolimus-eluting stent and were discharged on dual antiplatelet therapy with ticagrelor or prasugrel. Only those patients with a very low platelet reactivity level (platelet reactivity units ≤ 30) based on VerifyNow 1 month after discharge will be included. The primary endpoint is a composite of cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, and bleeding at 1-year follow-up.</p><p><strong>Results: </strong>The EPIC17-VERONICA study (NCT04654052) will reveal the efficacy profile of the de-escalation strategy, based on the VerifyNow platelet aggregation test, and determine the role of this device in the selection of patients who are eligible to benefit from this strategy.</p><p><strong>Conclusions: </strong>This study will determine whether platelet function testing provide clinical benefit in the management of patients with ACS.</p>","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"8 2","pages":"94-99"},"PeriodicalIF":1.5,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148977918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An interview with Camino Bañuelos.","authors":"Pilar Jiménez Quevedo, Ana Belén Cid Álvarez","doi":"10.24875/RECICE.M25000550","DOIUrl":"10.24875/RECICE.M25000550","url":null,"abstract":"","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"8 1","pages":"65-66"},"PeriodicalIF":1.5,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13137340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Off-label use of rotational atherectomy in STEMI: a single-center experience.","authors":"Alicia Prieto-Lobato, Beatriz Vaquerizo Montilla, Juan Carlos Betancourt-Villarruel, Héctor Cubero Gallego, Xavier Armario, Helena Tizón-Marcos","doi":"10.24875/RECICE.M25000552","DOIUrl":"10.24875/RECICE.M25000552","url":null,"abstract":"","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"8 2","pages":"119-121"},"PeriodicalIF":1.5,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DEB or DES for the treatment of calcified nodules after intravascular lithotripsy: the DEBSCAN-IVL trial design.","authors":"Alfonso Jurado-Román, Mattia Basile, José M Montero-Cabezas, Borja Rivero-Santana, Jon Zubiaur, Julio García-Tejada, Guillermo Galeote, Santiago Jiménez-Valero, Armando Pérez de Prado, Arturo García-Tuchard, Daniel Tebar, José Ramón Rumoroso, Ariana Gonzálvez, Ignacio J Amat-Santos, Víctor Alfonso Jiménez-Díaz, Eva Rumiz, Jorge Sanz-Sánchez, Beatriz Vaquerizo, Fernando Alfonso, Raúl Moreno","doi":"10.24875/RECICE.M25000551","DOIUrl":"10.24875/RECICE.M25000551","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Calcified coronary nodules (CN) are among the most challenging lesions for percutaneous coronary intervention, as drug-eluting stents (DES) frequently result in suboptimal expansion, malapposition, and recurrent adverse events. Although intravascular lithotripsy (IVL) provides effective plaque modification, the optimal definitive strategy remains unclear. Drug-eluting balloons (DEB) have demonstrated potential in the treatment of complex lesions in which stent implantation may be less desirable. This trial aims to compare the safety and efficacy profile of DEB vs DES after IVL in patients with CN.</p><p><strong>Methods: </strong>We conducted a retrospective, investigator-initiated, multicenter, non-inferiority, randomized clinical trial.</p><p><strong>Results: </strong>A total of 128 patients with de novo CN confirmed by intracoronary imaging in vessels measuring 2.5 mm to 4.0 mm in diameter will be enrolled across 10 high-volume percutaneous coronary intervention centers. After lesion preparation with IVL, patients will be randomized on a 1:1 ratio to receive a DEB or a DES. The co-primary endpoints are late lumen loss and net luminal gain at 9 ± 1 months of angiographic follow-up, both assessed by an independent core laboratory. Secondary endpoints include procedural, angiographic, and clinical outcomes, adjudicated by a blinded clinical events committee. Clinical follow-up will be conducted at 1 month, 1 year, and 2 years.</p><p><strong>Conclusions: </strong>The DEBSCAN-IVL trial will provide the first randomized evidence comparing DEB and DES after IVL for CN.Registered at ClinicalTrials.gov: NCT06657833.</p>","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"8 2","pages":"100-106"},"PeriodicalIF":1.5,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter aortic valve implantation without immediate cardiac surgery backup. A single-center retrospective analysis.","authors":"António Rocha de Almeida, Renato Fernandes, Ângela Bento, David Neves, Diogo Brás, Gustavo Mendes, Rita Rocha, Marta Paralta Figueiredo, Rafael Viana, Rita Louro, Álvaro Laranjeira Santos, Lino Patrício","doi":"10.24875/RECICE.M25000549","DOIUrl":"10.24875/RECICE.M25000549","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Transcatheter aortic valve implantation (TAVI) is traditionally performed with on-site cardiac surgery (CS) backup. However, procedural advances enabled TAVI to be performed safely without immediate CS backup. This study describes our single-center experience with TAVI performed in a center without on-site CS backup.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of the first 300 patients undergoing TAVI without on-site CS backup between 2020 and 2024. The primary endpoint was 30-day mortality. Secondary endpoints included procedural and in-hospital mortality, stroke, emergency cardiac surgery (ECS), vascular complications, major hemorrhage, and pacemaker implantation. Outcomes were compared with those from the Portuguese national TAVI registry.</p><p><strong>Results: </strong>The cohort mean age was 82±5 years (54% women). The median STS risk score was 3.8 [IQR, 2.3-6.6], with 17% high-risk patients (STS > 8). Most procedures were elective (83%). Transfemoral access was used in 99% of cases, and self-expandable valves were implanted in 95%. The 30-day mortality rate was 3.7% (n = 11), while stroke occurred in 2.7% (n = 8). The procedural survival rate was 99% (n = 298). No cases of ECS occurred (n = 0), coronary obstruction, TAVI-in-TAVI deployment as a bailout, or valve embolization were reported. Pericardial tamponade occurred in 0.7% of cases (n = 2). Major hemorrhage and vascular complications occurred in 8%, and pacemaker implantation in 20%. The 1-year mortality rate was 12%, with 4% attributed to cardiovascular causes; among survivors, and 91% reported symptomatic improvement. There were no significant differences in outcomes vs the results from the TAVI national registry.</p><p><strong>Conclusions: </strong>TAVI was safely and effectively performed without on-site CS, including emergency and complex cases. The non-ECS rate and outcomes comparable to national benchmarks support the feasibility of TAVI in selected non-CS centers. In this context, expanding TAVI access may reduce waiting times and improve the management of severe aortic stenosis while maintaining high procedural quality.</p>","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"8 2","pages":"72-78"},"PeriodicalIF":1.5,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial septal defect closure with cor triatriatum sinister.","authors":"Ana Abrantes, Eddiana Colón, Eduardo Pozo Osinalde, Daniel García-Arribas, Luis Nombela-Franco, Pablo Salinas","doi":"10.24875/RECICE.M25000543","DOIUrl":"https://doi.org/10.24875/RECICE.M25000543","url":null,"abstract":"","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"8 3","pages":"200-201"},"PeriodicalIF":1.5,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13539272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148931366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optical coherence tomography for the diagnosis and management of stent thrombosis.","authors":"Paula Antuña, Javier Cuesta, Fernando Rivero, Teresa Bastante, Marcos García-Guimaraes, David Del Val, Alexander Marschall, Lidia Vilches, César Morís, Pablo Avanzas, Fernando Alfonso","doi":"10.24875/RECICE.M25000540","DOIUrl":"10.24875/RECICE.M25000540","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Stent thrombosis (ST) is a rare but potentially fatal complication of percutaneous coronary interventions. With its high spatial resolution, optical coherence tomography (OCT) allows identification of underlying mechanical causes of stent thrombosis that may be overlooked by conventional angiography.</p><p><strong>Methods: </strong>We conducted a prospective, single-center registry that consecutively included patients with a definitive diagnosis of ST who underwent OCT at the acute presentation. The presence of underlying mechanical abnormalities was assessed, and their likelihood as the primary cause of ST was determined. In-hospital and follow-up prognosis was evaluated.</p><p><strong>Results: </strong>A total of 105 patients were included in the final analysis. Mechanical abnormalities were identified by the OCT in 87% of cases and deemed the most probable cause of ST in 77.1%. Findings varied significantly by timing of stent thrombosis: in acute cases, no mechanical abnormality was most common (41.8%); in subacute cases, stent underexpansion predominated (47.8%); in late cases, malapposition was most frequent (30.8%); and in very late cases, neoatherosclerosis was the leading cause (52%). However, no significant differences were found in relation to the type of stent involved. In all cases, treatment was tailored to correct the detected abnormality, with a new stent being implanted in 52% of patients. There were no OCT-related complications.</p><p><strong>Conclusions: </strong>OCT is a safe and valuable tool in the assessment of ST as it allows the identification of distinct causative mechanisms according to timing of ST and helps optimize the management of patients experiencing this rare but serious complication.</p>","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"8 2","pages":"85-93"},"PeriodicalIF":1.5,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148978148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of angiography-derived physiological assessment techniques in the post-FAVOR III Europe era?","authors":"Adrián Jerónimo, Enrique Gutiérrez-Ibañes","doi":"10.24875/RECICE.M25000546","DOIUrl":"10.24875/RECICE.M25000546","url":null,"abstract":"","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"8 1","pages":"5-7"},"PeriodicalIF":1.5,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13137338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"REC: Interventional Cardiology is now indexed in PubMed Central, the ultimate indexing.","authors":"José M de la Torre-Hernández, Fernando Alfonso, Raúl Moreno, Soledad Ojeda, Armando Pérez de Prado, Rafael Romaguera","doi":"10.24875/RECICE.M25000541","DOIUrl":"10.24875/RECICE.M25000541","url":null,"abstract":"","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"7 4","pages":"195-201"},"PeriodicalIF":1.5,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12666642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145662278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}